Woodline Partners LP Trims Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Woodline Partners LP reduced its stake in Arrowhead Pharmaceuticals by 33.1%, holding 562,175 shares worth approximately $7.16 million after selling 277,999 shares in the first quarter.
• Insider James C. Hamilton sold 15,000 shares of Arrowhead stock for $375,000, resulting in a decreased ownership of 5.72% and leaving him with 247,122 shares valued at around $6.18 million.
• Arrowhead Pharmaceuticals reported a quarterly loss of ($1.26) earnings per share (EPS), missing the expectations, with a revenue of $27.77 million compared to anticipated revenue of $29.01 million.

Woodline Partners LP lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 33.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 562,175 shares of the biotechnology company's stock after selling 277,999 shares during the quarter. Woodline Partners LP owned approximately 0.41% of Arrowhead Pharmaceuticals worth $7,162,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $49,000. CWM LLC boosted its position in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 2,523 shares in the last quarter. KBC Group NV boosted its position in Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 2,132 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Arrowhead Pharmaceuticals during the 1st quarter valued at $133,000. Institutional investors own 62.61% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on ARWR shares. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Chardan Capital reaffirmed a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Royal Bank Of Canada dropped their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 2nd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 2.6%

Shares of Arrowhead Pharmaceuticals stock traded up $0.75 during trading on Tuesday, reaching $29.42. The company's stock had a trading volume of 1,992,359 shares, compared to its average volume of 2,047,918. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $4.07 billion, a price-to-earnings ratio of -22.98 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $31.13. The company has a 50-day simple moving average of $20.23 and a two-hundred day simple moving average of $16.59.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period last year, the business earned ($1.38) EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the transaction, the insider owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 25,000 shares of company stock valued at $575,000. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.